布地奈德雾化吸入联合孟鲁司特钠治疗小儿CVA的疗效分析  

Efficacy analysis of budesonide aerosol inhalation combined with montelukast sodium in the treatment of cough variant asthma in children

作　　者：仇丽琴[1] 茅渊[2] 居家华 QIU Li-qin;MAO Yuan;JU Jia-hua(Gaoyou People’s Hospital,Gaoyou 225600,China)

机构地区：[1]江苏省高邮市人民医院,225600 [2]江苏省苏北人民医院,225001

出　　处：《中国实用医药》2021年第26期115-117,共3页China Practical Medicine

摘　　要：目的观察布地奈德雾化吸入结合孟鲁司特钠在小儿咳嗽变异性哮喘(CVA)治疗中的应用效果。方法60例CVA患儿,按照系统抽样法分为对照组和观察组,每组30例。对照组患儿采用布地奈德雾化吸入治疗,观察组患儿采用布地奈德雾化吸入结合孟鲁司特钠治疗。比较两组临床治疗效果,肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)和FEV1/FVC],咳嗽改善时间,炎症指标[肿瘤坏死因子-α(TNF-α)和白细胞介素-4(IL-4)]。结果观察组治疗总有效率93.33%高于对照组的73.33%,差异具有统计学意义(χ^(2)=4.320,P=0.038<0.05)。治疗前,两组FEV1、FVC、FEV1/FVC水平比较差异无统计学意义(P>0.05);治疗后,观察组FEV1、FVC、FEV1/FVC水平高于对照组,差异具有统计学意义(P<0.05)。观察组咳嗽改善时间为(5.10±1.58)d,短于对照组的(8.67±2.13)d,差异具有统计学意义(t=7.373,P=0.000<0.05)。治疗前,两组TNF-α和IL-4水平比较差异无统计学意义(P>0.05);治疗后,观察组TNF-α和IL-4水平均低于对照组,差异具有统计学意义(P<0.05)。结论给予CVA患儿布地奈德雾化吸入结合孟鲁司特钠治疗,有助于患儿咳嗽等症状及早减轻,改善其肺功能,且可提高治疗效果,值得临床应用与推广。Objective To observe the practical effect of budesonide aerosol inhalation combined with montelukast sodium in the treatment of cough variant asthma(CVA)in children.Methods A total of 60 children with CVA were divided into a control group and an observation group according to the systematic sampling method,with 30 cases in each group.The control group was treated with budesonide aerosol inhalation,and the observation group was treated with budesonide aerosol inhalation and montelukast sodium.The clinical effect,pulmonary function indicators[forced vital capacity(FVC),forced expiratory volume in the 1st second(FEV1)and FEV1/FVC],cough improvement time,inflammation indicators[tumor necrosis factor-α(TNF-α)and interleukin-4(IL-4)]were compared between the two groups.Results The total effective rate was 93.33%in the observation group,which was higher than 73.33%in the control group,and the difference was statistically significant(χ^(2)=4.320,P=0.038<0.05).Before treatment,there was no statistically significant difference in the levels of FEV1,FVC,FEV1/FVC between the two groups(P>0.05).After treatment,the levels of FEV1,FVC,FEV1/FVC in the observation group were higher than those in the control group,and the difference was statistically significant(P<0.05).The cough improvement time was(5.10±1.58)d in the observation group,which was shorter than(8.67±2.13)d in the control group,and the difference was statistically significant(t=7.373,P=0.000<0.05).Before treatment,there was no statistically significant difference in the levels of TNF-αand IL-4 between the two groups(P>0.05).After treatment,the levels of TNF-αand IL-4 in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).Conclusion Combination of budesonide aerosol inhalation and montelukast sodium can help children with CVA to relieve cough and improve their lung function,and promote the treatment effect,which is worthy of clinical application and promotion.

关 键 词：小儿咳嗽变异性哮喘 孟鲁司特钠 布地奈德雾化吸入 

分 类 号：R725.6[医药卫生—儿科]